Brewster Ursula C
Department of Medicine, Section of Nephrology, Yale University School of Medicine, New Haven, Connecticut 06520-8029, USA.
Semin Dial. 2006 Jul-Aug;19(4):285-90. doi: 10.1111/j.1525-139X.2006.00174.x.
Intravenous iron therapy is instrumental in the management of anemia in patients with end-stage renal disease (ESRD). Iron is available in several different preparations, with slight differences in the pharmacology of each. Given the importance of intravenous iron in the management of these patients, clinicians should be aware of the potential risks associated with it. Intravenous iron has effects on host immunity that raise concerns about clinical infection risk. Iron preparations appear to increase oxidative stress in these patients, which has important implications for cardiovascular disease states. Lastly, the effects of intravenous iron on liver disease are largely unknown.
静脉铁剂治疗在终末期肾病(ESRD)患者贫血的管理中发挥着重要作用。铁剂有几种不同的制剂,每种制剂的药理学略有差异。鉴于静脉铁剂在这些患者管理中的重要性,临床医生应意识到与之相关的潜在风险。静脉铁剂对宿主免疫有影响,这引发了对临床感染风险的担忧。铁剂制剂似乎会增加这些患者的氧化应激,这对心血管疾病状态具有重要意义。最后,静脉铁剂对肝脏疾病的影响在很大程度上尚不清楚。